Dianthus Therapeutics, Inc.
A clinical-stage biotech developing antibody therapies for severe autoimmune diseases, Dianthus Therapeutics is built around its lead candidate, claseprubart, a selective C1s inhibitor designed for convenient subcutaneous self-injection and now in late-stage trials for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. A second candidate, DNTH212, targets immune signals behind these diseases. The company holds worldwide development and commercial rights to its medicines outside Greater China.
Granted 834.3K · Bought 108.9K
Sold 14.2K
Bought 1.25M · Sold 14.2K
Sold 3.70M
Granted 1.50M
Granted 166.7K
Bought 6.6K
Granted 56.0K · Bought 400 · Sold 126.3K
Sold 52.5K
Granted 5.0K · Sold 12.1K
Sold 19.7K
Granted 188.2K · Sold 122.9K
Granted 26.0K · Sold 5.7K
Granted 26.0K · Sold 6.1K
Granted 26.0K · Sold 6.2K
Granted 23.0K · Sold 5.7K
Granted 20.0K · Sold 5.7K
Granted 20.0K · Sold 5.7K
Granted 30.0K · Sold 30.0K
Granted 33.9K · Sold 33.9K
Granted 256.9K · Bought 4.0K · Sold 256.9K
Granted 43.7K · Sold 43.7K
Granted 162.6K · Sold 162.6K
Granted 28.8K · Sold 28.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +2 co-filersDirector, 10% owner · 6 transactions | — | 13.97Mas of Jan 2024 | 834.3K | 108.9K | — |
| Atlas Venture Associates X, L.P. +2 co-filers10% owner · 4 transactions | — | 8.97Mas of Mar 2019 | — | — | 14.2K |
| Booth BruceDirector · 5 transactions | — | 5.37Mas of Jul 2020 | — | 1.25M | 14.2K |
| Alphabet Inc. +3 co-filers10% owner · 1 transaction | — | 3.34Mas of Jun 2018 | — | — | — |
| Byers BlakeDirector · 1 transaction | — | 3.34Mas of Jun 2018 | — | — | — |
| Atlas Venture Fund X, L.P.10% owner · 1 transaction | — | 3.15Mas of Feb 2021 | — | — | — |
| TRV GP IV, LLC +2 co-filers10% owner · 4 transactions | — | 3.06Mas of Feb 2023 | — | — | 3.70M |
| Avidity Partners Management (GP) LLC +4 co-filersDirector · 1 transaction | — | 2.72Mas of Jan 2024 | 1.50M | — | — |
| Moulder Leon O JrDirector · 1 transaction | — | 2.71Mas of Jan 2024 | 166.7K | — | — |
| Fairmount Funds Management LLC +1 co-filerDirector · 3 transactions | — | 2.70Mas of Oct 2024 | — | — | — |
| Scadden DavidDirector · 2 transactions | — | 1.58Mas of Jun 2018 | — | 6.6K | — |
| Gardner JasonSee Remarks, Director · 14 transactions | — | 945.0Kas of Dec 2022 | 56.0K | 400 | 126.3K |
| Ronneberg Amy LDirector · 1 transaction | — | 593.6Kas of Jun 2018 | — | — | — |
| Cooke Michael P.Chief Scientific Officer · 15 transactions | — | 244.4Kas of Dec 2019 | — | — | 52.5K |
| Zdraveski ZoranSee Remarks · 6 transactions | — | 140.9Kas of Dec 2019 | 5.0K | — | 12.1K |
| Daniel Thomas ODirector · 1 transaction | — | 101.9Kas of Jun 2018 | — | — | — |
| Isacson Christina K.Chief Business Officer · 4 transactions | — | 83.8Kas of Dec 2019 | — | — | 19.7K |
| Bonney Michael WDirector · 2 transactions | — | 65.3Kas of Feb 2019 | — | — | — |
| Garcia MarinoCEO AND PRESIDENT, Director · 8 transactions | — | 65.3K | 188.2K | — | 122.9K |
| Stants KristenChief People Officer · 4 transactions | — | 20.3Kas of Nov 2022 | 26.0K | — | 5.7K |
| Beetham Thomas W.See Remarks · 4 transactions | — | 19.9Kas of Nov 2022 | 26.0K | — | 6.1K |
| Deardorf CarenChief Commercial Officer · 4 transactions | — | 19.8Kas of Nov 2022 | 26.0K | — | 6.2K |
| Mahoney Stephen F.See Remarks · 3 transactions | — | 17.3Kas of Nov 2022 | 23.0K | — | 5.7K |
| Nichols David WayneChief Technical Officer · 2 transactions | — | 14.3Kas of Sep 2021 | 20.0K | — | 5.7K |
| Olson LisaSee Remarks · 2 transactions | — | 14.3Kas of Sep 2021 | 20.0K | — | 5.7K |
| Veness Adam MSVP, General Counsel and Sec. · 3 transactions | — | 13.2K | 30.0K | — | 30.0K |
| Davis John C. JrChief Medical Officer · 10 transactions | — | 8.3Kas of Jan 2020 | 33.9K | — | 33.9K |
| Randhawa SimratEVP, Head of R&D · 23 transactions | — | 8.0K | 256.9K | 4.0K | 256.9K |
| Carr EdwardCHIEF ACCOUNTING OFFICER · 8 transactions | — | 4.4K | 43.7K | — | 43.7K |
| Albers Jeffrey W.Director · 1 transaction | — | 4.2Kas of Jun 2018 | — | — | — |
| Borisy AlexisDirector · 2 transactions | — | 4.1Kas of Aug 2021 | — | — | — |
| Savitz RyanEVP, CFO & CBO · 16 transactions | — | 0 | 162.6K | — | 162.6K |
| Soteropoulos PaulaDirector · 6 transactions | — | 0 | 28.8K | — | 28.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -3.28M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.